Recombinant factor VIIa treatment for life-threatening haemoptysis.
Diffuse alveolar haemorrhage is a severe clinical disorder that may be life-threatening. The early diagnosis of diffuse alveolar haemorrhage and prompt intervention is crucial. Recombinant factor VIIa has been used extensively for the treatment of haemophilia A and B patients. More recently, recombinant factor VIIa has been used successfully for the treatment of bleeding in patients without pre-existing coagulopathy. We describe the successful use of recombinant factor VIIa in a patient with diffuse alveolar haemorrhage secondary to pulmonary-renal syndrome.
Yildirim
Huseyin
H
Department of Chest Disease, Osmangazi University, Medical Faculty, 26480 Meselik, Eskisehir, Turkey. heylul2002@yahoo.com
Ucgun
Irfan
I
Yalcin
Ahmet Ugur
AU
Gulbaş
Zafer
Z
Sahin
Garip
G
Acikalin
Mustafa Fuat
MF
Metintas
Muzaffer
M
Ak
Guntulu
G
D000328:Adult; D003029:Coagulants / Q000627:therapeutic use*; D015942:Factor VIIa / Q000627:therapeutic use*; D006469:Hemoptysis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D011650:Pulmonary Alveoli; D011994:Recombinant Proteins / Q000627:therapeutic use
D003029:Coagulants; D011994:Recombinant Proteins; D015942:Factor VIIa